Pediatric Nephrology

, Volume 22, Issue 7, pp 911–914 | Cite as

The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection

Editorial Commentary

Abstract

Acute rejection with vascular involvement remains a challenging problem in renal allotransplantation. Fibrinoid necrosis of the arteries with secondary thrombotic occlusions is C4d negative in 50% of cases and has the worst prognosis among all allograft vascular lesions. Nonhuman leukocyte antigen (HLA) non-complement-fixing antibodies reacting to artery-specific antigens have been speculated to be responsible for causing severe vascular injury. We recently reported the presence of agonistic antibodies against the angiotensin II type 1 receptor (AT1R-AA) in 16 recipients of renal allografts who had severe vascular rejection and malignant hypertension but who did not have anti-HLA antibodies. AT1R-AA stimulate AT1R and induce mediators of inflammation and thrombosis. Removal of AT1R-AA by plasmapheresis in combination with pharmacologic AT1R blockade leads to improved renal function and graft survival in AT1R-AA-positive patients. We have shown that the analysis of the subtle diagnostic and mechanistic differences may help to identify patients at particular risk and improve outcome of rejections with vascular pathology.

Keywords

Vascular rejection Non-HLA antibodies Alloantibodies Angiotensin II AT1 receptor Kidney transplantation 

References

  1. 1.
    Meier-Kriesche HU, Schold JD, Kaplan B (2004) Long-term renal allograft survival: have we made significant progress or is it time time to rethink our analytic and therapeutic strategies. Am J Transplant 4:1289–1295PubMedCrossRefGoogle Scholar
  2. 2.
    Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Fitzpatrick D, Farrell ML, Collins AB, Williams WW, Delmonico FL, Cosimi AB, Colvin RB, Saidmann SL (2001) Acute humoral rejection in renal allograft recipients: incidence, serology and clinical characteristics. Transplantation 71:652–658PubMedCrossRefGoogle Scholar
  3. 3.
    Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidmann SL, Tolkoff-Rubin N, Williams WW, Delmonico FL, Cosimi AB, Colvin RB (2002) Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classfication. J Am Soc Nephrol 13:779–787PubMedGoogle Scholar
  4. 4.
    Nickeleit V, Vamvakas EC, Pascual M, Poletti BJ, Colvin RB (1998) The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 9:1301–1308PubMedGoogle Scholar
  5. 5.
    Halloran PF, Schlaut J, Solez K, Srinivasa NS (1992) The significance of the anti-class I response II clinical and pathological features of renal transplants with anti-class I-like antibody. Transplantation 53:550–555PubMedCrossRefGoogle Scholar
  6. 6.
    Vongwiwatana A, Tasanarong A, HIdalgo LG, Halloran PF (2003) The role of B cells and alloantibody in the host response to human organ allograft. Immunol Rev 196:197–218PubMedCrossRefGoogle Scholar
  7. 7.
    Böhmig G, Exner M, Habicht A, Soleiman A, Schilinger M, Lang U, Hörl WH, Watschinger B, Derfler K, Regele H (2002) Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13:1091–1099PubMedGoogle Scholar
  8. 8.
    Nickeleit V, Mihatsch MJ (2003) Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 18:2232–2239PubMedCrossRefGoogle Scholar
  9. 9.
    Rose M (2004) Role of MHC and non-MHC antibodies in graft rejection. Curr Opin Organ Transplant 9:16–23CrossRefGoogle Scholar
  10. 10.
    Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y (2001) Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells. Arthritis Rheum 44:1484–1494PubMedCrossRefGoogle Scholar
  11. 11.
    Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G (2005) Angiotensin II type 1-receptor activating antibodies in renal allograft rejection. N Engl J Med 352:558–569PubMedCrossRefGoogle Scholar
  12. 12.
    Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC (1999) Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. J Clin Invest 1103:945–952Google Scholar
  13. 13.
    Fu MI, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J (2000) Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 18:945–953PubMedCrossRefGoogle Scholar
  14. 14.
    Mellor AL, Munn DH (2000) Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 18:367–391PubMedCrossRefGoogle Scholar
  15. 15.
    Dobado Berrios P, Lopez-Pedrera C, Velasco F, Cudrado MJ (2001) The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 44:2467–2476PubMedCrossRefGoogle Scholar
  16. 16.
    Touyz R (2005) Molecular and cellular mechanisms in vascular injury and hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 14:125–131PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2007

Authors and Affiliations

  1. 1.Department of Nephrology and Intensive Care Medicine Campus Virchow-Klinikum and Center for Cardiovascular Research Medical Faculty of the Charité BerlinBerlinGermany
  2. 2.Department of Nephrology and Intensive Care Medicine, Charité Campus Virchow ClinicBerlinGermany

Personalised recommendations